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dSafety First” was coined in an advertisement for flecainide
any years ago. The advertisement was made when the
APS (Cardiac Arrhythmia Pilot Study) (1) demonstrated
hat flecainide was highly effective in removing ventricular
remature beats from the electrocardiogram in patients who
ad a prior myocardial infarction. That was a time of
nnocence and optimism in the area of antiarrhythmic
rugs. The innocence and optimism was torn heavily when
AST (Cardiac Arrhythmia Suppression Trial) (2) revealed
hat the drugs that so effectively reduced post-myocardial
nfarction arrhythmias were hazardous for patients. But the
ptimism was not torn completely apart. While the risk of
everal antiarrhythmic drugs was noted for high-risk pa-
ients, it was assumed that they would be safe for patients
ith few risk factors. Perhaps physicians and even author-
ties assume that drugs that have been on the market for
any years without serious complaints are safe. Recent
istory has shown this to be wrong. Selective cyclooxygen-
se (COX)-2 inhibitors were given to millions of patients
ithout serious complaints, and only when trials were
crutinized were the cardiovascular risks revealed (3,4).
iclofenac, one of the most widely used nonsteroidal
nti-inflammatory drugs for nearly a generation, is in fact a
elective COX-2 inhibitor, and this drug may also be unsafe
or patients who have had a myocardial infarction or even
or apparently healthy people (5,6). Many years of use of a
rug is clearly not a substitute for a formal study of safety.
After the CAST experience, Pfizer developed dofetilide and
as required to perform formal studies on high-risk patients to
valuate the safety of the drug (7,8). Even though these trials
stablished acceptable safety, dofetilide was never a huge
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or Novartis and Sanofi Aventis.uccess, probably because of the risk of torsade de pointes
entricular tachycardia and a complicated dosing schedule.
During the development of dronedarone, Sanofi-Aventis
as requested to perform a safety study similar to that of the
IAMOND (Danish Investigations of Arrhythmia and
ortality on Dofetilide) trials, and the ANDROMEDA
Antiarrhythmic Trial With Dronedarone in Moderate-to-
evere CHF Evaluating Morbidity Decrease) ensued (9).
he study was based on the DIAMOND-CHF (Conges-
ive Heart Failure) trial design and used an end point that,
f used in the DIAMOND-CHF trial as the primary end
oint, would have come out with significance of benefit.
NDROMEDA was stopped prematurely because of an
xcess mortality with dronedarone. As rightly pointed out
y Singh et al. (10) in this issue of the Journal, there is no
xplanation for the finding. The story of dronedarone might
ave ended there, but instead, the ATHENA (A Placebo-
ontrolled, Double-Blind, Parallel Arm Trial to Assess the
fficacy of Dronedarone 400 mg bid for the Prevention of
ardiovascular Hospitalization or Death From Any Cause
n Patients With Atrial Fibrillation/Atrial Flutter) trial was
onducted and came out with a positive result. This is the
rst large trial to provide safety data in a moderate risk
opulation that comprises a large part of the relevant
atients for rhythm control therapy.
ow efficacious is dronedarone compared to other anti-
rrhythmic drugs for maintenance of sinus rhythm?
ronedarone has been formally compared with amiodarone
nd was clearly less efficacious in maintaining sinus rhythm.
he effect of dronedarone is moderate, as demonstrated in
he review by Singh et al. (10), but all antiarrhythmic drugs
ave moderate efficacy. Any attempt to compare dronedar-
ne with flecainide, sotalol, or other drugs on the market is
utile because there are no comparable trials, and compari-
on with historical data is often misleading. Amiodarone
emains the leader among antiarrhythmic drugs in terms of
fficacy (11)—other drugs have moderate effectiveness.
hus, in terms of efficacy, dronedarone is probably not a
tep forward, but whether it is more or less efficacious than
ecainide, sotalol, and propafenone when rhythm control is
ursued needs to be tested in randomized trials.
ow safe is dronedarone compared to other antiarrhythmic
rugs? Singh et al. (10) boldly state that flecainide,
ropafenone, and sotalol are safe for large groups of pa-
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Antiarrhythmic Drugs: Safety First April 13, 2010:1577–9ients. It is fair to examine the evidence for such a claim for
rugs recommended for the maintenance of sinus rhythm in
uidelines (12).
LECAINIDE. A recent meta-analysis (13) examined the
fficacy and safety of drugs for maintaining sinus rhythm.
eventy-one patients were exposed to flecainide in placebo-
ontrolled trials and 132 in trials with a comparator. No
eaths were observed. Wehling (14) identified all random-
zed studies with flecainide involving patients without signs
f left ventricular failure. A total of 2,015 years of exposure
ere found, and there were 8 deaths. Finally, the CAST
learly demonstrated that flecainide should not be used for
atients with left ventricular failure (2).
ROPAFENONE. The meta-analysis by Lafuente-Lafuente
t al. (13) was able to identify 720 propafenone-treated
atients with no deaths in placebo-controlled trials of
aintenance of sinus rhythm and 1 death among 152
atients in a comparison with flecainide.
OTALOL. The meta-analysis by Lafuente-Lafuente et al.
13) identified 30 deaths among 1,391 patients treated with
otalol and 5 deaths among 815 patients treated with
lacebo (p  0.06). In comparisons with quinidine and
miodarone, there were 56 deaths among 1,316 patients
reated with sotalol versus 41 deaths among 1,572 patients
reated with amiodarone or quinidine. Also important to
ote is the post-myocardial infarction trial including 1,452
atients (15) in which sotalol was associated with a statis-
ically insignificant reduction of mortality.
MIODARONE. The meta-analysis of studies for mainte-
ance of sinus rhythm found 13 deaths among 428 patients
andomly allocated to amiodarone versus 3 of 245 patients
llocated to placebo (p  NS). In comparator trials, there
ere 38 deaths among 704 patients randomly assigned to
miodarone versus 65 deaths of 704 patients randomly as-
igned to other drugs. Finally, a series of large studies has
emonstrated that amiodarone does not increase death among
atients with ischemic heart disease and heart failure (16).
OFETILIDE. The meta-analysis includes 83 dead among
31 patients randomly assigned to dofetilide and 83 among
45 patients randomly assigned to placebo. The high mortality
eflects that selected patients from the DIAMOND studies
7,8) were included. The DIAMOND studies included
3,000 patients in total with left ventricular dysfunction and
ither heart failure or a recent myocardial infarction. These
tudies were neutral with respect to mortality.
RONEDARONE. Four placebo-controlled studies of atrial
brillation used a dronedarone dose of 800 mg daily
17–19). In total, these document 125 dead among 3,214
atients randomly allocated to dronedarone and 142 deaths
mong 2,825 randomly allocated to placebo. The
NDROMEDA study conducted with heart failure pa-
ients was terminated early because of increased mortality.
ronedarone reduced cardiovascular hospitalizationsmong patients by 24% in the ATHENA study, and such a
irect clinical benefit has not been demonstrated for any
ther antiarrhythmic drug.
Singh et al. (10) provide many calculations of 95%
ignificance interval for mortality in various subgroups
reated with dronedarone. It should be noted that any
ttempt to make such calculations for other available anti-
rrhythmic drugs would result in confidence limits that
nclude very high risks. If “safety first” is the issue, the data
or dronedarone are superior to those of other antiarrhyth-
ic drugs for low/moderate-risk patients.
oes dronedarone change the rate versus rhythm treatment
ption? Two large trials have shown equivalence between
ate control and rhythm control therapy, with rhythm
ontrol mostly based on treatment with amiodarone (20,21).
hile insignificant, the balance was slightly in favor of rate
ontrol therapy. Singh et al. (10) consider rate control
herapy the first choice for many patients, which is probably
orrect for those who are eligible for the preceding studies.
evertheless, rhythm control is the chosen therapy for many
atients. The problems arise when an antiarrhythmic drug is
onsidered necessary to maintain sinus rhythm or is pre-
erred by the patient. So far, decent advice would require
hat patients are informed of the unknown safety of most
ompounds and of the common problems with long-term
miodarone therapy. With dronedarone, it is for the first
ime possible to provide reassurance to large groups of
ow-risk patients. More patients will possibly accept antiar-
hythmic therapy to maintain sinus rhythm.
hich drugs are first-line therapy for maintenance of
inus rhythm in atrial fibrillation? For patients with heart
ailure, dronedarone brings no news. Dofetilide and amio-
arone are still the only drugs with proven safety for these
atients. For intermediate-risk patients, dronedarone pro-
ides another option with an uncertain placement. Al-
hough dronedarone should clearly not be used for patients
ith severe heart failure, the safety of most antiarrhythmic
rugs for intermediate-risk patients is uncertain. For pa-
ients with low risk, dronedarone provides the only antiar-
hythmic drug with a large safety database to prove reason-
ble safety. The safety knowledge of dronedarone may result
n patient and physician preference of dronedarone as
rst-line therapy, with a possible switch to amiodarone
hen sinus rhythm is no longer maintained.
eprint requests and correspondence: Dr. Christian Torp-
edersen, Department of Cardiology, Gentofte Hospital, Univer-
ity of Copenhagen, Niels Andersens Vej, 2900 Hellerup, Den-
ark. E-mail: ctp@heart.dk.
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